recombinant interleukin-7

BIOLOGICAL4 trials

Sponsors

National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI), Cytheris SA, M.D. Anderson Cancer Center

Conditions

Acute Myeloid LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveCord Blood Transplant RecipientKidney CancerMelanoma (Skin)Myelodysplastic SyndromeMyeloproliferative NeoplasmUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Interleukin-7 in Treating Patients With Refractory Solid Tumors

CompletedNCT00062049

National Institutes of Health Clinical Center (CC)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2003-04-30End: 2011-05-31Target: 30Updated: 2012-03-08

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

CompletedNCT00091338

National Cancer Institute (NCI)Melanoma (Skin)

Start: 2004-08-31Updated: 2015-04-30

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

TerminatedNCT00492440

Cytheris SAKidney Cancer, Melanoma (Skin)

Start: 2007-05-31End: 2010-12-31Updated: 2012-10-18

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

CompletedNCT03941769

M.D. Anderson Cancer CenterAcute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cord Blood Transplant Recipient +2

Start: 2020-09-29End: 2023-03-01Updated: 2024-10-17